Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
ALX Oncology Inc.
Pfizer
Pfizer
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited
Pheon Therapeutics
Revolution Medicines, Inc.
Seagen Inc.
Alterome Therapeutics, Inc.
Orano Med LLC
RasCal Therapeutics, Inc.
Pfizer
Xencor, Inc.
Cartography Biosciences
Accent Therapeutics
Mirati Therapeutics Inc.
Pheon Therapeutics
Novartis
Novartis
AstraZeneca
Chongqing Precision Biotech Co., Ltd
HUYABIO International, LLC.
HUYABIO International, LLC.
Medigen Biotechnology Corporation
Elicio Therapeutics
Revolution Medicines, Inc.
Eli Lilly and Company
Novita Pharmaceuticals, Inc.
Compugen Ltd
Sapience Therapeutics
Black Diamond Therapeutics, Inc.
Toray Industries, Inc
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Amal Therapeutics
Compugen Ltd
Mirati Therapeutics Inc.
Hutchmed
ADC Therapeutics S.A.
HiberCell, Inc.
Chongqing Precision Biotech Co., Ltd
Chongqing Precision Biotech Co., Ltd
Minneamrita Therapeutics LLC
Cancer Insight, LLC
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Genzada Pharmaceuticals USA, Inc.
Genentech, Inc.
Provectus Pharmaceuticals